$VXRT Sucky day for $JNJ with the news of their COVID trial. You know. They could open the Universal Influenza pre-clinical trial report VAXART prepared, and read it. They will surely find important and news worthy information in there regarding trial results. Who knows. They may even find VAXART to be an ideal partner. Focused on the same core values. With strong science, valuable IP, and top notch staff.
  • 9